• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic Acid (CAS No. 1006464-16-9)

2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic acid is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. This compound, identified by the Chemical Abstracts Service Number (CAS No.) 1006464-16-9, belongs to the pyrazole class of molecules, which are known for their broad spectrum of biological interactions. Pyrazole derivatives have been extensively studied for their roles in drug development, particularly in the modulation of enzyme activities and receptor binding.

The molecular structure of 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic acid features two pyrazole rings linked through an acetic acid moiety. The presence of a methyl group at the 1-position of one pyrazole ring and the acetic acid side chain at the 1-position of the second pyrazole ring contributes to its distinct chemical and pharmacological properties. This arrangement allows for diverse interactions with biological targets, making it a promising candidate for further investigation in medicinal chemistry.

In recent years, there has been a surge in research focused on developing novel therapeutic agents with improved efficacy and reduced side effects. The pyrazole scaffold has emerged as a key structural motif in this endeavor, owing to its ability to mimic natural products and interact with various biological pathways. Studies have shown that pyrazole derivatives can exhibit anti-inflammatory, antimicrobial, and anticancer properties, among others. The compound 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic acid is no exception, and its potential applications are being explored in several areas of medical research.

One of the most compelling aspects of this compound is its potential role in modulating enzyme activities relevant to metabolic disorders. Recent advancements in computational chemistry have enabled researchers to predict the binding affinities of small molecules to target enzymes with high accuracy. Using molecular docking simulations, scientists have identified that 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic acid can interact with key enzymes involved in glucose metabolism and lipid synthesis. These interactions may lead to the development of novel treatments for conditions such as diabetes and hyperlipidemia.

Furthermore, the compound has shown promise in preclinical studies as a potential inhibitor of kinases, which are enzymes that play critical roles in cell signaling pathways. Dysregulation of kinase activities is implicated in various diseases, including cancer and autoimmune disorders. The dual pyrazole structure of 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-ylacetic acid allows it to bind to multiple kinase targets simultaneously, potentially leading to synergistic therapeutic effects. This multitargeting capability is a desirable feature in drug design, as it can reduce the likelihood of resistance development.

The synthesis of 2-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazol-1-yloic acid has been optimized by several research groups to enhance yield and purity. Advanced synthetic techniques, such as transition metal-catalyzed cross-coupling reactions, have been employed to construct the complex heterocyclic framework efficiently. These methods not only improve the accessibility of the compound but also allow for structural modifications that can fine-tune its biological activity. The availability of high-quality starting materials and well-established synthetic protocols has facilitated rapid progress in exploring its pharmacological potential.

Recent clinical trials have begun to evaluate the safety and efficacy of derivatives similar to 2-(3-(4-methylpyrazolyl)pyrazolyl)acetic acid in human subjects. While results are still preliminary, early findings suggest that this class of compounds may have significant therapeutic value without causing severe adverse effects. This aligns with broader trends in drug development, where there is a growing emphasis on identifying agents that are both effective and well-tolerated by patients.

The future direction of research on 2-(3-(4-methylpyrazol)pyrazo]l)acetic acid will likely involve further exploration of its mechanisms of action and optimization for clinical use. Combination therapies using this compound alongside other drugs may also be investigated to enhance treatment outcomes. Additionally, computational modeling techniques will continue to play a crucial role in guiding synthetic efforts and predicting biological responses.

In conclusion,CAS No 1006464 16 9 refers to a novel heterocyclic compound with promising pharmaceutical applications. Its unique structural features and ability to interact with multiple biological targets make it an attractive candidate for further research. As our understanding of disease mechanisms continues to evolve,(this compound) along with other pyrazole derivatives will undoubtedly play an important role in shaping the future landscape of drug development.

• 647824-51-9(1-tert-butyl-3,5-dimethyl-1H-pyrazole-4-carbaldehyde)
• 120800-48-8(1H-Pyrazole-3-carboxylicacid, 1-acetyl-5-methyl-)
• 50920-65-5(1-Ethyl-3-methyl-1H-pyrazole-5-carboxylic acid)
• 120982-59-4(N-(3-(Diethylamino)propyl)-2-(3,4-diphenyl-1H-pyrazol-1-yl)acetamide)
• 93323-67-2(Pyrazole-1-acetic Acid, 3,5-diphenyl-)
• 25016-20-0(1-Methyl-1H-pyrazole-3-carboxylic acid)
• 942631-65-4(1-(propan-2-yl)-1H-pyrazole-3-carboxylic acid)
• 682757-49-9(Ethyl 1-(tert-butyl)-1H-pyrazole-3-carboxylate)
• 120982-79-8(1H-Pyrazole-1-aceticacid, 3,4-diphenyl-, ethyl ester)
• 124344-98-5((1-Methyl-5-phenyl-1H-pyrazol-3-yl)methanol)